Literature DB >> 32517959

Molecular Tumor Boards in Clinical Practice.

Claudio Luchini1, Rita T Lawlor2, Michele Milella3, Aldo Scarpa4.   

Abstract

Next-generation sequencing (NGS) application in clinical practice requires the implementation of molecular tumor boards (MTBs). Starting from a systematic review of literature, we discuss the MTB-related key points: MTB aims and composition, types of tumors to discuss, types of molecular analyses, methods for classifying actionability, appropriate turnaround time, and cost management.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MTB; molecular tumor board; personalized medicine; precision oncology; target therapy

Mesh：

Substances：

Year:  2020        PMID： 32517959     DOI： 10.1016/j.trecan.2020.05.008

Source DB:  PubMed          Journal:  Trends Cancer        ISSN： 2405-8025


  25 in total

1.  Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer Center.

Authors:  Neha M Jain; Lauren Schmalz; Christopher Cann; Adara Holland; Travis Osterman; Katie Lang; Georgia L Wiesner; Tuya Pal; Christine Lovly; Thomas Stricker; Christine Micheel; Justin M Balko; Douglas B Johnson; Ben Ho Park; Wade Iams
Journal:  Oncologist       Date:  2021-09-08

2.  Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.

Authors:  Coren A Milbury; James Creeden; Wai-Ki Yip; David L Smith; Varun Pattani; Kristi Maxwell; Bethany Sawchyn; Ole Gjoerup; Wei Meng; Joel Skoletsky; Alvin D Concepcion; Yanhua Tang; Xiaobo Bai; Ninad Dewal; Pei Ma; Shannon T Bailey; James Thornton; Dean C Pavlick; Garrett M Frampton; Daniel Lieber; Jared White; Christine Burns; Christine Vietz
Journal:  PLoS One       Date:  2022-03-16       Impact factor: 3.240

3.  Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France).

Authors:  Marius Ilié; Véronique Hofman; Christophe Bontoux; Simon Heeke; Virginie Lespinet-Fabre; Olivier Bordone; Sandra Lassalle; Salomé Lalvée; Virginie Tanga; Maryline Allegra; Myriam Salah; Doriane Bohly; Jonathan Benzaquen; Charles-Hugo Marquette; Elodie Long-Mira; Paul Hofman
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

Review 4.  Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards.

Authors:  Edoardo Crimini; Matteo Repetto; Paolo Tarantino; Liliana Ascione; Gabriele Antonarelli; Elena Guerini Rocco; Massimo Barberis; Luca Mazzarella; Giuseppe Curigliano
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

Review 5.  Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer.

Authors:  Sabine Grill; Evelyn Klein
Journal:  Breast Care (Basel)       Date:  2021-01-20       Impact factor: 2.860

6.  Knowledge bases and software support for variant interpretation in precision oncology.

Authors:  Florian Borchert; Andreas Mock; Aurelie Tomczak; Jonas Hügel; Samer Alkarkoukly; Alexander Knurr; Anna-Lena Volckmar; Albrecht Stenzinger; Peter Schirmacher; Jürgen Debus; Dirk Jäger; Thomas Longerich; Stefan Fröhling; Roland Eils; Nina Bougatf; Ulrich Sax; Matthieu-P Schapranow
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

7.  Distribution of Genomic Testing Resources by Oncology Practice and Rurality: A Nationally Representative Study.

Authors:  Brittany Gardner; Michelle Doose; Janeth I Sanchez; Andrew N Freedman; Janet S de Moor
Journal:  JCO Precis Oncol       Date:  2021-06-22

8.  Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience.

Authors:  Michelle F Green; Jonathan L Bell; Christopher B Hubbard; Shannon J McCall; Matthew S McKinney; Jinny E Riedel; Carolyn S Menendez; James L Abbruzzese; John H Strickler; Michael B Datto
Journal:  JCO Precis Oncol       Date:  2021-09-16

Review 9.  Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.

Authors:  Shreya M Shah; Elena V Demidova; Randy W Lesh; Michael J Hall; Mary B Daly; Joshua E Meyer; Martin J Edelman; Sanjeevani Arora
Journal:  Cancer Treat Rev       Date:  2022-01-05       Impact factor: 13.608

10.  Postgraduate training in Cancer Genetics-a cross-specialty survey exploring experience of clinicians in Ireland.

Authors:  Jana K McHugh; Gozie Offiah; Sean Daly; Nazmy El Beltagi; Michael Kevin Barry; Seamus O'Reilly; Terri P McVeigh
Journal:  Ir J Med Sci       Date:  2021-06-30       Impact factor: 2.089
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.